ACLARIS THERAPEUTICS INC (ACRS)
US00461U1051 - Common Stock
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
Biotech's Role in Addressing the Pancreatic Cancer Emergency
/PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers...
Commit To Purchase Aclaris Therapeutics At $0.50, Earn 23.4% Annualized Using Options
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
HW Wainwright cuts Aclaris to neutral, cites underwhelming study data (NASDAQ:ACRS)
HC Wainwright has downgraded Aclaris Therapeutics (ACRS) to neutral, citing underwhelming data from a Phase 2 study for its drug ATI-1777 in the treatment of at
Aclaris stock spikes on strategic review (NASDAQ:ACRS)
Aclaris Therapeutics stock (ACRS) rises as the company begin a strategic review with a leadrship change as co-founder Neal Walker returns to CEO role. Read more here.
Aclaris stock downgraded at BTIG despite eczema trial win
BTIG downgraded Aclaris Therapeutics (ACRS) Thursday even after the company said its eczema therapy, ATI-1777, succeeded in a mid-stage trial. Find out the reasons.
Aclaris stock downgraded at Jefferies despite eczema trial win
Aclaris Therapeutics (ACRS) stock falls as Jefferies downgrades despite positive results in a mid-stage trial for company's eczema therapy, ATI-1777. Read more here.
Aclaris stock falls after mid-stage data for eczema therapy
Aclaris Therapeutics (ACRS) stock falls after Phase 2b data for its JAK inhibitor ATI-1777 in eczema. Read more here.
Aclaris to slash 46% of workforce as it reprioritizes drug programs (ACRS)
Aclaris Therapeutics (ACRS) said it plans to slash around 46% of its workforce as its restructures and reprioritizes its drug programs. Read more here.
Aclaris Therapeutics Provides Corporate Update
- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces...
Commit To Buy Aclaris Therapeutics At $1, Earn 58.5% Annualized Using Options
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...